palmidrol has been researched along with Innate Inflammatory Response in 67 studies
palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection
palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| ", PEA co-ultramicronized with the natural antioxidant quercetin (PEA-Q), administered orally in two different rat models of inflammatory and OA pain, namely carrageenan paw oedema and sodium monoiodoacetate (MIA)-induced OA." | 7.85 | A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models. ( Britti, D; Crupi, R; Cuzzocrea, S; Di Paola, R; Evangelista, M; Fusco, R; Gugliandolo, E; Impellizzeri, D; Morittu, VM; Schievano, C, 2017) |
| " The antiinflammatory activity of synthetic cannabinoid nabilone in the rat model of carrageenan-induced acute hindpaw inflammation was compared with that of the endocannabinoid palmitoylethanolamide and the nonsteroidal antiinflammatory drug indomethacin." | 7.71 | Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. ( Colleoni, M; Conti, S; Costa, B; Giagnoni, G; Parolaro, D, 2002) |
| " (1) The therapeutic effects of the cannabinoid anandamide and the putative CB2 agonist palmitoylethanolamide were tested in a model of persistent visceral pain (turpentine inflammation of the urinary bladder)." | 7.70 | The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. ( Hasnie, FS; Jaggar, SI; Rice, AS; Sellaturay, S, 1998) |
| "Anandamide, an endogenous ligand at the CB1 cannabinoid receptor and palmitoylethanolamide (a putative endogenous ligand at the CB2 receptor) have both been shown to possess anti-hyperalgesic properties in models of somatic and visceral inflammation." | 7.70 | The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat urinary bladder. ( Jaggar, SI; Rice, AS; Sellaturay, S, 1998) |
| " anandamide (arachidonoylethanolamide, AEA), 2-arachidonoylglycerol (2-AG) and palmitoylethanolamide (PEA), in the control of inflammation and of the proliferation of tumor cells is reviewed here." | 4.80 | Cannabimimetic fatty acid derivatives in cancer and inflammation. ( Bisogno, T; De Petrocellis, L; Di Marzo, V; Melck, D, 2000) |
| ", PEA co-ultramicronized with the natural antioxidant quercetin (PEA-Q), administered orally in two different rat models of inflammatory and OA pain, namely carrageenan paw oedema and sodium monoiodoacetate (MIA)-induced OA." | 3.85 | A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models. ( Britti, D; Crupi, R; Cuzzocrea, S; Di Paola, R; Evangelista, M; Fusco, R; Gugliandolo, E; Impellizzeri, D; Morittu, VM; Schievano, C, 2017) |
| "N-acylethanolamines (NAEs) such as N-palmitoylethanolamine and anandamide are endogenous bioactive lipids having numerous functions, including the control of inflammation." | 3.85 | N-acylethanolamine-hydrolyzing acid amidase and fatty acid amide hydrolase inhibition differentially affect N-acylethanolamine levels and macrophage activation. ( Alhouayek, M; Bottemanne, P; Makriyannis, A; Muccioli, GG, 2017) |
| " Intraplantar injection of CAR led to a time-dependent development of peripheral inflammation, in terms of paw edema, cytokine release in paw exudates, nitrotyrosine formation, inducible nitric oxide synthase and cyclooxygenase-2 expression." | 3.83 | A new co-micronized composite containing palmitoylethanolamide and polydatin shows superior oral efficacy compared to their association in a rat paw model of carrageenan-induced inflammation. ( Bruschetta, G; Cordaro, M; Crupi, R; Cuzzocrea, S; Esposito, E; Gugliandolo, E; Impellizzeri, D; Siracusa, R, 2016) |
| ") on upper gastrointestinal transit in control mice and in mice with chronic intestinal inflammation induced by croton oil." | 3.71 | Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. ( Capasso, F; Capasso, R; Di Marzo, V; Fezza, F; Izzo, AA; Mascolo, N; Pinto, A, 2001) |
| " The antiinflammatory activity of synthetic cannabinoid nabilone in the rat model of carrageenan-induced acute hindpaw inflammation was compared with that of the endocannabinoid palmitoylethanolamide and the nonsteroidal antiinflammatory drug indomethacin." | 3.71 | Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. ( Colleoni, M; Conti, S; Costa, B; Giagnoni, G; Parolaro, D, 2002) |
| " (1) The therapeutic effects of the cannabinoid anandamide and the putative CB2 agonist palmitoylethanolamide were tested in a model of persistent visceral pain (turpentine inflammation of the urinary bladder)." | 3.70 | The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. ( Hasnie, FS; Jaggar, SI; Rice, AS; Sellaturay, S, 1998) |
| "Anandamide, an endogenous ligand at the CB1 cannabinoid receptor and palmitoylethanolamide (a putative endogenous ligand at the CB2 receptor) have both been shown to possess anti-hyperalgesic properties in models of somatic and visceral inflammation." | 3.70 | The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat urinary bladder. ( Jaggar, SI; Rice, AS; Sellaturay, S, 1998) |
| "The management of the associated neuropathic pain remains difficult to treat." | 3.11 | A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain. ( Pickering, E; Rao, A; Steadman, KJ; Steels, EL; Vitetta, L, 2022) |
| " Provided that their respective bioavailability is properly addressed (e." | 2.82 | Palmitoylethanolamide and Related ALIAmides for Small Animal Health: State of the Art. ( Della Rocca, G; Re, G, 2022) |
| "Inflammation is fundamentally a protective cellular response aimed at removing injurious stimuli and initiating the healing process." | 2.52 | N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution. ( Barbierato, M; Bruschetta, G; Cuzzocrea, S; Facci, L; Giusti, P; Impellizzeri, D; Skaper, SD; Zusso, M, 2015) |
| "Among all types of chronic pain, neuropathic pain stands out: this is pain resulting from damage or disease of the somatosensory nervous system, and remains largely untreatable." | 2.50 | Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. ( Costa, B; Della Valle, MF; Facci, L; Fusco, M; Giusti, P; Skaper, SD; Zusso, M, 2014) |
| "Fucoxanthinol (FXOH) is a marine carotenoid from brown seaweeds with various beneficial effects." | 1.56 | Anti-Inflammatory Effects of Fucoxanthinol in LPS-Induced RAW264.7 Cells through the NAAA-PEA Pathway. ( Chen, W; Fang, H; Hong, Z; Jin, W; Li, L; Yang, L; Yi, Z; Zhang, G; Zhang, Y, 2020) |
| "Inflammation is a key element in the pathobiology of neurodegenerative diseases and sees the involvement of different neuronal and non-neuronal cells as players able to respond to inflammatory signals of immune origin." | 1.56 | Synergic Therapeutic Potential of PEA-Um Treatment and NAAA Enzyme Silencing In the Management of Neuroinflammation. ( Ardizzone, A; Campolo, M; Casili, G; Cuzzocrea, S; Esposito, E; Lanza, M; Paterniti, I; Scuderi, SA; Siracusa, R, 2020) |
| "Alcohol binge drinking is a heavy pattern of alcohol consumption increasingly used by young people." | 1.48 | Increased plasma oleoylethanolamide and palmitoleoylethanolamide levels correlate with inflammatory changes in alcohol binge drinkers: the case of HMGB1 in women. ( Alén, F; Antón, M; Ballesta, A; Correas, Á; de la Torre, R; Gómez de Heras, R; Orio, L; Pastor, A; Rodríguez de Fonseca, F; Rodríguez-González, A; Rodríguez-Rojo, IC; Serrano, A, 2018) |
| "In an aging society, Alzheimer's disease (AD) exerts an increasingly serious health and economic burden." | 1.48 | Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer's disease by exerting anti-inflammatory and neuroprotective effects. ( Bellanti, F; Broad, KD; Bronzuoli, MR; Canese, R; Carpinelli, G; Cassano, T; Facchinetti, R; Ferraro, L; Gaetani, S; Pace, L; Palombelli, G; Scuderi, C; Serviddio, G; Steardo, L, 2018) |
| "Since chronic inflammation is mainly driven by cells of adaptive immunity, particularly T lymphocytes, we aimed at investigating whether such bioactive lipids could directly modulate T-cell responses." | 1.48 | Bioactive lipids ALIAmides differentially modulate inflammatory responses of distinct subsets of primary human T lymphocytes. ( Chiurchiù, V; Leuti, A; Maccarrone, M; Mechoulam, R; Smoum, R, 2018) |
| "Obesity is associated with augmented peripheral inflammation and pain sensitivity in response to inflammatory stimulation, but the underlying mechanisms remain unclear." | 1.40 | Down-regulation of PPARα in the spinal cord contributes to augmented peripheral inflammation and inflammatory hyperalgesia in diet-induced obese rats. ( Fu, Z; Li, D; Liang, L; Wang, J; Zhang, Q; Zhao, L, 2014) |
| " The lipidic nature and large particle size of PEA in the native state may limit its solubility and bioavailability when given orally, however." | 1.40 | Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. ( Bruschetta, G; Cordaro, M; Crupi, R; Cuzzocrea, S; Esposito, E; Impellizzeri, D; Siracusa, R, 2014) |
| "Effects of pre-treatment with a single dose, versus 4 day repeated dosing with the selective FAAH inhibitor, URB597 (i." | 1.38 | Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system. ( Alexander, SP; Barrett, DA; Bennett, AJ; Burston, J; Chapman, V; Kendall, DA; Norris, LM; Okine, BN; Patel, A; Woodhams, S, 2012) |
| "Emerging evidence indicates that astrogliosis is involved in the pathogenesis of neurodegenerative disorders." | 1.37 | Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide. ( Arietti, P; Blasio, A; Carnuccio, R; De Filippis, D; Di Marzo, V; Esposito, G; Iuvone, T; Petrosino, S; Scuderi, C; Steardo, L; Valenza, M, 2011) |
| "Granuloma was induced by subcutaneous lambda-carrageenin-soaked sponge implants on the back of male Wistar rats." | 1.36 | Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. ( Cipriano, M; D'Amico, A; De Filippis, D; Di Marzo, V; Iuvone, T; Orlando, P; Petrosino, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (4.48) | 18.2507 |
| 2000's | 12 (17.91) | 29.6817 |
| 2010's | 38 (56.72) | 24.3611 |
| 2020's | 14 (20.90) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Lama, A | 1 |
| Pirozzi, C | 1 |
| Severi, I | 1 |
| Morgese, MG | 1 |
| Senzacqua, M | 1 |
| Annunziata, C | 1 |
| Comella, F | 1 |
| Del Piano, F | 1 |
| Schiavone, S | 1 |
| Petrosino, S | 8 |
| Mollica, MP | 1 |
| Diano, S | 1 |
| Trabace, L | 1 |
| Calignano, A | 3 |
| Giordano, A | 1 |
| Mattace Raso, G | 2 |
| Meli, R | 3 |
| Ozaki, T | 1 |
| Kamiyama, N | 1 |
| Saechue, B | 1 |
| Soga, Y | 1 |
| Gotoh, R | 1 |
| Nakayama, T | 1 |
| Fukuda, C | 1 |
| Dewayani, A | 1 |
| Chalalai, T | 1 |
| Ariki, S | 1 |
| Ozaka, S | 1 |
| Sonoda, A | 1 |
| Hirose, H | 1 |
| Gendo, Y | 1 |
| Noguchi, K | 1 |
| Sachi, N | 1 |
| Hidano, S | 1 |
| Maeshima, K | 1 |
| Gotoh, K | 1 |
| Masaki, T | 1 |
| Ishii, K | 1 |
| Osada, Y | 1 |
| Shibata, H | 1 |
| Kobayashi, T | 1 |
| Pickering, E | 1 |
| Steels, EL | 1 |
| Steadman, KJ | 1 |
| Rao, A | 1 |
| Vitetta, L | 1 |
| Della Rocca, G | 1 |
| Re, G | 2 |
| Peritore, AF | 3 |
| Siracusa, R | 8 |
| Crupi, R | 7 |
| Cuzzocrea, S | 16 |
| Piomelli, D | 5 |
| Scalvini, L | 1 |
| Fotio, Y | 1 |
| Lodola, A | 2 |
| Spadoni, G | 1 |
| Tarzia, G | 2 |
| Mor, M | 2 |
| Jin, W | 1 |
| Yang, L | 1 |
| Yi, Z | 1 |
| Fang, H | 1 |
| Chen, W | 1 |
| Hong, Z | 1 |
| Zhang, Y | 1 |
| Zhang, G | 1 |
| Li, L | 1 |
| Gigante, A | 1 |
| Aquili, A | 1 |
| Farinelli, L | 1 |
| Caraffa, A | 1 |
| Ronconi, G | 1 |
| Enrica Gallenga, C | 1 |
| Tetè, G | 1 |
| Kritas, SK | 1 |
| Conti, P | 1 |
| Casili, G | 2 |
| Lanza, M | 2 |
| Campolo, M | 2 |
| Paterniti, I | 3 |
| Ardizzone, A | 2 |
| Scuderi, SA | 1 |
| Esposito, E | 10 |
| Schiano Moriello, A | 1 |
| Fusco, R | 4 |
| Impellizzeri, D | 9 |
| Esposito, G | 4 |
| Pesce, M | 1 |
| Seguella, L | 1 |
| Lu, J | 1 |
| Corpetti, C | 1 |
| Del Re, A | 1 |
| De Palma, FDE | 1 |
| Sanseverino, W | 1 |
| Sarnelli, G | 1 |
| Colizzi, M | 1 |
| Bortoletto, R | 1 |
| Costa, R | 1 |
| Zoccante, L | 1 |
| Clayton, P | 1 |
| Hill, M | 1 |
| Bogoda, N | 1 |
| Subah, S | 1 |
| Venkatesh, R | 1 |
| D'Amico, R | 2 |
| Cordaro, M | 7 |
| Gugliandolo, E | 4 |
| Genovese, T | 1 |
| Di Paola, R | 6 |
| Stensson, N | 1 |
| Ghafouri, B | 1 |
| Gerdle, B | 1 |
| Ghafouri, N | 1 |
| Britti, D | 1 |
| Schievano, C | 2 |
| Morittu, VM | 1 |
| Evangelista, M | 2 |
| Sasso, O | 2 |
| Summa, M | 1 |
| Armirotti, A | 1 |
| Pontis, S | 1 |
| De Mei, C | 1 |
| Antón, M | 1 |
| Rodríguez-González, A | 1 |
| Rodríguez-Rojo, IC | 1 |
| Pastor, A | 1 |
| Correas, Á | 1 |
| Serrano, A | 1 |
| Ballesta, A | 1 |
| Alén, F | 1 |
| Gómez de Heras, R | 1 |
| de la Torre, R | 1 |
| Rodríguez de Fonseca, F | 1 |
| Orio, L | 1 |
| Scuderi, C | 2 |
| Bronzuoli, MR | 1 |
| Facchinetti, R | 1 |
| Pace, L | 1 |
| Ferraro, L | 1 |
| Broad, KD | 1 |
| Serviddio, G | 1 |
| Bellanti, F | 1 |
| Palombelli, G | 1 |
| Carpinelli, G | 1 |
| Canese, R | 1 |
| Gaetani, S | 1 |
| Steardo, L | 4 |
| Cassano, T | 1 |
| Chiurchiù, V | 1 |
| Leuti, A | 1 |
| Smoum, R | 1 |
| Mechoulam, R | 1 |
| Maccarrone, M | 2 |
| Gorelik, A | 1 |
| Gebai, A | 1 |
| Illes, K | 1 |
| Nagar, B | 1 |
| Kytikova, O | 1 |
| Novgorodtseva, T | 1 |
| Antonyuk, M | 1 |
| Denisenko, Y | 1 |
| Gvozdenko, T | 1 |
| Couch, DG | 1 |
| Cook, H | 1 |
| Ortori, C | 1 |
| Barrett, D | 1 |
| Lund, JN | 1 |
| O'Sullivan, SE | 1 |
| Descalzi, F | 1 |
| Ulivi, V | 1 |
| Cancedda, R | 1 |
| Piscitelli, F | 1 |
| Luongo, L | 1 |
| Guida, F | 1 |
| Gatta, L | 1 |
| Maione, S | 1 |
| Di Marzo, V | 13 |
| Navarra, M | 1 |
| Skaper, SD | 4 |
| Facci, L | 4 |
| Fusco, M | 2 |
| Della Valle, MF | 2 |
| Zusso, M | 2 |
| Costa, B | 3 |
| Giusti, P | 2 |
| Capasso, R | 3 |
| Orlando, P | 4 |
| Pagano, E | 1 |
| Aveta, T | 2 |
| Buono, L | 1 |
| Borrelli, F | 1 |
| Izzo, AA | 3 |
| Russo, R | 3 |
| Alhouayek, M | 3 |
| Muccioli, GG | 3 |
| Wang, J | 1 |
| Zhang, Q | 1 |
| Zhao, L | 1 |
| Li, D | 1 |
| Fu, Z | 1 |
| Liang, L | 1 |
| Bruschetta, G | 6 |
| Bottemanne, P | 2 |
| Subramanian, KV | 1 |
| Lambert, DM | 1 |
| Makriyannis, A | 2 |
| Cani, PD | 1 |
| Barbierato, M | 1 |
| Tremolada, G | 1 |
| Maestroni, A | 1 |
| Bandello, F | 1 |
| Zerbini, G | 1 |
| Puigdemont, A | 1 |
| Verde, R | 1 |
| Allarà, M | 1 |
| Caltagirone, C | 1 |
| Cisari, C | 1 |
| Cristino, L | 1 |
| Karsak, M | 1 |
| Gaffal, E | 1 |
| Ueda, N | 1 |
| Tüting, T | 1 |
| Bisogno, T | 2 |
| De Filippis, D | 5 |
| D'Amico, A | 3 |
| Saturnino, C | 1 |
| Zimmer, A | 1 |
| Iuvone, T | 6 |
| Solorzano, C | 1 |
| Zhu, C | 1 |
| Battista, N | 1 |
| Astarita, G | 1 |
| Rivara, S | 1 |
| Antonietti, F | 1 |
| Duranti, A | 1 |
| Tontini, A | 1 |
| Cipriano, M | 1 |
| Blasio, A | 1 |
| Valenza, M | 1 |
| Arietti, P | 1 |
| Carnuccio, R | 1 |
| Okine, BN | 1 |
| Norris, LM | 1 |
| Woodhams, S | 1 |
| Burston, J | 1 |
| Patel, A | 1 |
| Alexander, SP | 1 |
| Barrett, DA | 1 |
| Kendall, DA | 1 |
| Bennett, AJ | 1 |
| Chapman, V | 1 |
| Negro, L | 1 |
| Vaia, M | 1 |
| Cinelli, MP | 2 |
| Balvers, MG | 1 |
| Verhoeckx, KC | 1 |
| Meijerink, J | 1 |
| Wortelboer, HM | 1 |
| Witkamp, RF | 1 |
| Conti, S | 2 |
| Giagnoni, G | 2 |
| Colleoni, M | 2 |
| Darmani, NA | 1 |
| Degenhardt, B | 1 |
| Valenti, M | 1 |
| Scaglione, G | 1 |
| Sorrentini, I | 1 |
| Barbero, R | 1 |
| Miolo, A | 1 |
| Breathnach, R | 1 |
| Hoareau, L | 1 |
| Ravanan, P | 1 |
| Gonthier, MP | 1 |
| Delarue, P | 1 |
| Gonçalves, J | 1 |
| Césari, M | 1 |
| Festy, F | 1 |
| Roche, R | 1 |
| D'Agostino, G | 1 |
| La Rana, G | 1 |
| Iacono, A | 1 |
| Raso, GM | 1 |
| Lo Verme, J | 1 |
| Dalle Carbonare, M | 1 |
| Del Giudice, E | 1 |
| Stecca, A | 1 |
| Colavito, D | 1 |
| Fabris, M | 1 |
| D'Arrigo, A | 1 |
| Bernardini, D | 1 |
| Dam, M | 1 |
| Leon, A | 2 |
| Dal Toso, R | 1 |
| Romanello, S | 1 |
| Buriani, A | 1 |
| Jaggar, SI | 2 |
| Hasnie, FS | 1 |
| Sellaturay, S | 2 |
| Rice, AS | 2 |
| Melck, D | 1 |
| De Petrocellis, L | 1 |
| Fezza, F | 1 |
| Pinto, A | 1 |
| Capasso, F | 1 |
| Mascolo, N | 1 |
| Parolaro, D | 1 |
20 reviews available for palmidrol and Innate Inflammatory Response
| Article | Year |
|---|---|
Palmitoylethanolamide and Related ALIAmides for Small Animal Health: State of the Art.
Topics: Amides; Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Ethanolamines; Humans; Inflammation; Palmit | 2022 |
Therapeutic Efficacy of Palmitoylethanolamide and Its New Formulations in Synergy with Different Antioxidant Molecules Present in Diets.
Topics: Amides; Animals; Anti-Inflammatory Agents; Antioxidants; Diet, Healthy; Dietary Supplements; Drug Sy | 2019 |
Topics: Amides; Amidohydrolases; Amino Acid Sequence; Animals; Anti-Inflammatory Agents; Cysteine; Enzyme In | 2020 |
Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries-A Systematic Review.
Topics: Alzheimer Disease; Amides; Amyotrophic Lateral Sclerosis; Animals; Autism Spectrum Disorder; Endocan | 2020 |
Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence.
Topics: Amides; Animals; Apoptosis; Autism Spectrum Disorder; Brain; Down-Regulation; Endocannabinoids; Etha | 2021 |
Palmitoylethanolamide: A Natural Compound for Health Management.
Topics: Amides; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Dietary Suppleme | 2021 |
Molecular Targets of Fatty Acid Ethanolamides in Asthma.
Topics: Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Eosinophils; Ethanolamines; Fatty | 2019 |
Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain.
Topics: Amides; Animals; Endocannabinoids; Ethanolamines; Humans; Inflammation; Mast Cells; Neuralgia; Neuro | 2014 |
Palmitoylethanolamide in CNS health and disease.
Topics: Amides; Animals; Anti-Inflammatory Agents; Central Nervous System; Ethanolamines; Humans; Inflammati | 2014 |
Harnessing the anti-inflammatory potential of palmitoylethanolamide.
Topics: Amides; Amidohydrolases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ethanolamines; Humans; In | 2014 |
N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution.
Topics: Administration, Oral; Amides; Amidohydrolases; Animals; Anti-Inflammatory Agents; Antidepressive Age | 2015 |
The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.
Topics: Amides; Analgesics; Animals; Anti-Inflammatory Agents; Chemistry, Pharmaceutical; Dietary Supplement | 2017 |
N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities.
Topics: Amides; Animals; Anti-Inflammatory Agents; Endocannabinoids; Ethanolamines; Humans; Inflammation; Pa | 2010 |
Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma.
Topics: Amides; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Endocannabinoids; Ethanolamine | 2013 |
Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide.
Topics: Amides; Animals; Cell Communication; Central Nervous System; Endocannabinoids; Ethanolamines; Humans | 2012 |
New insights in mast cell modulation by palmitoylethanolamide.
Topics: Amides; Animals; Clinical Trials as Topic; Endocannabinoids; Ethanolamines; Humans; Hyperalgesia; In | 2013 |
Measurement of palmitoylethanolamide and other N-acylethanolamines during physiological and pathological conditions.
Topics: Amides; Animals; Chromatography, Liquid; Dietary Fats; Endocannabinoids; Energy Metabolism; Ethanola | 2013 |
Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies.
Topics: Amides; Animals; Cannabinoid Receptor Modulators; Clinical Trials as Topic; Colitis, Ulcerative; Dia | 2005 |
Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals.
Topics: Amides; Analgesics; Animals; Cannabinoids; Endocannabinoids; Ethanolamines; Inflammation; Pain; Palm | 2007 |
Cannabimimetic fatty acid derivatives in cancer and inflammation.
Topics: Adjuvants, Immunologic; Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Age | 2000 |
2 trials available for palmidrol and Innate Inflammatory Response
| Article | Year |
|---|---|
A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain.
Topics: Australia; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans; Inflammation; Neuralgia; Treatm | 2022 |
Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo-A Randomized, Placebo-controlled, Double-blind Controlled Trial.
Topics: Adolescent; Adult; Amides; Anti-Inflammatory Agents, Non-Steroidal; Caco-2 Cells; Cannabidiol; Cell | 2019 |
45 other studies available for palmidrol and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice.
Topics: Amides; Animals; Anxiety; Diet, High-Fat; Ethanolamines; Hypothalamo-Hypophyseal System; Inflammatio | 2022 |
Comprehensive lipidomics of lupus-prone mice using LC-MS/MS identifies the reduction of palmitoylethanolamide that suppresses TLR9-mediated inflammation.
Topics: Amides; Animals; Chromatography, Liquid; Ethanolamines; Inflammation; Interleukin-6; Lipidomics; Mic | 2022 |
Anti-Inflammatory Effects of Fucoxanthinol in LPS-Induced RAW264.7 Cells through the NAAA-PEA Pathway.
Topics: Amides; Amidohydrolases; Animals; Anti-Inflammatory Agents; beta Carotene; Cytokines; Enzyme Inhibit | 2020 |
Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19.
Topics: Amides; Animals; Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cromol | 2020 |
Synergic Therapeutic Potential of PEA-Um Treatment and NAAA Enzyme Silencing In the Management of Neuroinflammation.
Topics: Amides; Amidohydrolases; Animals; Biomarkers; Cell Line; Cell Survival; Disease Management; Disease | 2020 |
Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-l-Carnitine on Experimental Model of Inflammatory Pain.
Topics: Acetylcarnitine; Amides; Animals; Carrageenan; Cell Count; Cyclooxygenase 2; Disease Models, Animal; | 2021 |
Engineered
Topics: Amides; Animals; Colitis; Dextran Sulfate; Disease Models, Animal; Ethanolamines; Humans; Inflammati | 2021 |
Management of Acute Lung Injury: Palmitoylethanolamide as a New Approach.
Topics: Acute Lung Injury; Amides; Animals; Cytokines; Ethanolamines; Immunohistochemistry; Inflammation; In | 2021 |
Alterations of anti-inflammatory lipids in plasma from women with chronic widespread pain - a case control study.
Topics: Adult; Aged; Amides; Anti-Inflammatory Agents; Chronic Pain; Cytokines; Endocannabinoids; Ethanolami | 2017 |
A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models.
Topics: Administration, Oral; Amides; Animals; Anti-Inflammatory Agents; Carrageenan; Drug Combinations; Ede | 2017 |
The N-Acylethanolamine Acid Amidase Inhibitor ARN077 Suppresses Inflammation and Pruritus in a Mouse Model of Allergic Dermatitis.
Topics: Amides; Amidohydrolases; Animals; Carbamates; Dermatitis, Allergic Contact; Dinitrofluorobenzene; Di | 2018 |
Increased plasma oleoylethanolamide and palmitoleoylethanolamide levels correlate with inflammatory changes in alcohol binge drinkers: the case of HMGB1 in women.
Topics: Amides; Anthropometry; Binge Drinking; Biomarkers; Case-Control Studies; Central Nervous System Depr | 2018 |
Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer's disease by exerting anti-inflammatory and neuroprotective effects.
Topics: Age Factors; Alzheimer Disease; Amides; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Be | 2018 |
Bioactive lipids ALIAmides differentially modulate inflammatory responses of distinct subsets of primary human T lymphocytes.
Topics: Amides; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytokines; Endocannabinoids; Ethanol | 2018 |
Molecular mechanism of activation of the immunoregulatory amidase NAAA.
Topics: Amides; Amidohydrolases; Analgesics; Animals; Catalytic Domain; Cell Line; Drug Discovery; Enzyme In | 2018 |
The neuroprotective effects of micronized PEA (PEA-m) formulation on diabetic peripheral neuropathy in mice.
Topics: Amides; Analgesics; Animals; Anti-Inflammatory Agents; Apoptosis; Cytokines; Diabetic Neuropathies; | 2019 |
Platelet-rich plasma exerts antinociceptive activity by a peripheral endocannabinoid-related mechanism.
Topics: Amides; Analgesics; Animals; Arachidonic Acids; Blotting, Western; Cell Line, Tumor; Endocannabinoid | 2013 |
A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury.
Topics: Amides; Animals; Blotting, Western; Cell Survival; Coloring Agents; Cyclooxygenase 2; Drug Combinati | 2013 |
Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB₁ receptors and TRPV1 channels.
Topics: Amides; Animals; Colitis; Disease Models, Animal; Ethanolamines; Gastrointestinal Motility; Inflamma | 2014 |
Down-regulation of PPARα in the spinal cord contributes to augmented peripheral inflammation and inflammatory hyperalgesia in diet-induced obese rats.
Topics: Amides; Animals; Diet, High-Fat; Down-Regulation; Ethanolamines; Hyperalgesia; Inflammation; Male; M | 2014 |
Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain.
Topics: Administration, Oral; Amides; Analgesics; Animals; Carrageenan; Chemistry, Pharmaceutical; Chromatog | 2014 |
N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis.
Topics: Amides; Amidohydrolases; Animals; Anti-Inflammatory Agents; Arachidonic Acids; Chromatography, High | 2015 |
Palmitoylethanolamide treatment reduces retinal inflammation in streptozotocin-induced diabetic rats.
Topics: Amides; Animals; Anti-Inflammatory Agents; Blood Glucose; Body Weight; Claudins; Cytokines; Diabetes | 2015 |
Adelmidrol increases the endogenous concentrations of palmitoylethanolamide in canine keratinocytes and down-regulates an inflammatory reaction in an in vitro model of contact allergic dermatitis.
Topics: Amides; Amidohydrolases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Membrane; Cell Survi | 2016 |
Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: from Rodent to Man.
Topics: Adult; Aged; Aged, 80 and over; Amides; Animals; Antioxidants; Behavior, Animal; Brain Ischemia; Coh | 2016 |
A new co-micronized composite containing palmitoylethanolamide and polydatin shows superior oral efficacy compared to their association in a rat paw model of carrageenan-induced inflammation.
Topics: Active Transport, Cell Nucleus; Administration, Oral; Amides; Animals; Carrageenan; Cell Line, Tumor | 2016 |
N-acylethanolamine-hydrolyzing acid amidase and fatty acid amide hydrolase inhibition differentially affect N-acylethanolamine levels and macrophage activation.
Topics: Amides; Amidohydrolases; Animals; Arachidonic Acids; Endocannabinoids; Ethanolamines; Gene Expressio | 2017 |
N-Palmitoylethanolamine-Oxazoline as a New Therapeutic Strategy to Control Neuroinflammation: Neuroprotective Effects in Experimental Models of Spinal Cord and Brain Injury.
Topics: Amides; Animals; Brain Injuries; Cytokines; Ethanolamines; Glial Fibrillary Acidic Protein; Inflamma | 2017 |
Protective role of palmitoylethanolamide in contact allergic dermatitis.
Topics: Amides; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Alle | 2010 |
Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation.
Topics: Amides; Amidohydrolases; Animals; Anti-Inflammatory Agents; Butyrates; Carrageenan; Catalytic Domain | 2009 |
Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats.
Topics: Amides; Amidohydrolases; Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Carrageenan; C | 2010 |
Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide.
Topics: Amides; Amyloid beta-Peptides; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; A | 2011 |
Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system.
Topics: Amides; Amidohydrolases; Animals; Arachidonic Acids; Behavior, Animal; Benzamides; Carbamates; Disea | 2012 |
Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems.
Topics: Acute Disease; Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; | 2002 |
The psychedelic haze of inflammation.
Topics: Amides; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cannabinoids; Endocann | 2007 |
Effect of PEA on LPS inflammatory action in human adipocytes.
Topics: Adipocytes; Adult; Amides; Cells, Cultured; Endocannabinoids; Ethanolamines; Humans; Inflammation; I | 2006 |
Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice.
Topics: Amides; Animals; Carrageenan; Central Nervous System; Drug Administration Routes; Edema; Endocannabi | 2007 |
A saturated N-acylethanolamine other than N-palmitoyl ethanolamine with anti-inflammatory properties: a neglected story...
Topics: Amides; Animals; Anti-Inflammatory Agents; Benzoxazines; Body Temperature; Camphanes; Cannabinoid Re | 2008 |
Adelmidrol, a palmitoylethanolamide analogue, reduces chronic inflammation in a carrageenin-granuloma model in rats.
Topics: Amides; Animals; Blotting, Western; Carrageenan; Cell Count; Chronic Disease; Dicarboxylic Acids; Do | 2009 |
Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide.
Topics: Amides; Animals; Arachidonic Acids; Base Sequence; Benzoxazines; Cannabinoids; Cell Membrane; Cells, | 1995 |
The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain.
Topics: Amides; Analgesics; Animals; Arachidonic Acids; Cannabinoids; Capillary Permeability; Cystitis; Elec | 1998 |
The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat urinary bladder.
Topics: Amides; Animals; Arachidonic Acids; Cannabinoids; Endocannabinoids; Ethanolamines; Female; Inflammat | 1998 |
Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice.
Topics: Adrenergic alpha-Antagonists; Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Camphanes; C | 2001 |
Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat.
Topics: Acute Disease; Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Camphanes; Cannabinoid Rece | 2002 |